Solabegron

Solabegron is a beta3-adrenergic receptor agonist that is currently under development for the treatment of overactive bladder and irritable bowel syndrome. It was initially developed by Arena Pharmaceuticals and is now being developed by Velicept Therapeutic.

History

Solabegron was first developed by Arena Pharmaceuticals. In 2013, Arena Pharmaceuticals granted exclusive worldwide rights to develop and commercialize Solabegron to Eisai Co., Ltd. However, in 2016, Velicept Therapeutic acquired the rights to Solabegron from Eisai Co., Ltd.

Mechanism of Action

Solabegron works by stimulating the beta3-adrenergic receptors in the bladder, which leads to relaxation of the bladder muscles. This helps to reduce the frequency of urination and the urgency to urinate, which are common symptoms of overactive bladder.

Clinical Trials

Several clinical trials have been conducted to evaluate the safety and efficacy of Solabegron. In a Phase 2 trial, Solabegron was found to be effective in reducing the symptoms of overactive bladder. A Phase 3 trial is currently underway.

Potential Side Effects

As with any medication, Solabegron may cause side effects. The most common side effects reported in clinical trials include headache, urinary tract infection, and dry mouth. However, these side effects were generally mild and did not lead to discontinuation of the medication.

See Also

• Beta3-adrenergic receptor
• Overactive bladder
• Irritable bowel syndrome
• Arena Pharmaceuticals
• Velicept Therapeutic

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia